Royalty Pharma invests in pharmaceutical and biotechnology product royalties and other revenue-producing intellectual property.

Royalty Pharma currently owns a diversified portfolio of royalties in 22 products: 16 leading approved and marketed pharmaceutical and pharmaceutical products, 5 products in Phase II clinical trials and/or under review with the FDA and 1 product in early stage of clinical development. The development of critical care treatments, therapies, and vaccines for life-threatening diseases, viruses, and other ailments form on of the cornerstones of the “cope” and “recover” aspects of Paladin’s homeland security investment strategy.

Royalty Pharma could potentially use Paladin’s investment funds to acquire interests in other treatments for various epidemic/pandemic diseases including those that could intentionally be used for bioterrorism. Neupogen/Neulasta, one of the largest products in Royalty Pharma’s current collection is a critical key medical countermeasure in the nation’s defense against terrorism in the event of a nuclear or radiological attack, such as a dirty bomb.

Importantly, the drug has been granted special approval by the FDA for deployment in the event of an emergency. Accordingly, the product is a vital tool in the defense of the nation, and is the only treatment currently held in the Strategic National Stockpile for treating Acute Radiation Sickness in the event of a mass casualty event.